Education
About Us
Working with TipRanks
Follow Us
Cel-Sci Corp. (CVM)
XASE:CVM
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$1.98 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$32.39M
Enterprise Value$30.94M
Total Cash (Recent Filing)$6.28M
Total Debt (Recent Filing)$10.63M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding8,457,967
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.03
Enterprise Value/Ebitda-1.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Immunotherapy FocusCEL-SCI centers on a single advanced clinical immunotherapy (Multikine) targeting head and neck cancer. A focused, late-stage therapeutic program creates a clear commercialization pathway and partnership potential; success would materially transform revenue prospects and strategic optionality.
Narrowing Net LossesConsistent reduction in net losses over multiple years signals improved cost discipline and operational efficiency. For a pre-revenue biotech, shrinking losses extend runway and reduce near-term financing pressure, improving the company’s ability to fund trials or negotiate non-dilutive partnerships.
More Moderate TTM LeverageDespite a reported 2025 anomaly, the TTM balance shows moderate leverage and a meaningful equity base. This more normal capital structure enhances financing flexibility and reduces immediate insolvency risk versus an otherwise extreme-debt scenario, supporting continued clinical development.
Bears Say
Pre-revenue ProfileThe company remains pre-revenue, which means all value depends on successful clinical outcomes and future commercialization. This structural dependency necessitates ongoing external funding, increases dilution or debt risk, and makes long-term profitability contingent on binary trial results.
Persistent Negative Cash FlowOperating cash flow has been consistently negative and averaged roughly -$17M TTM, creating a steady funding requirement. Persistent cash burn forces repeated capital raises or costly financing, compressing shareholder value and risking delays in clinical programs if capital access tightens.
Balance Sheet Volatility / Extreme 2025 DebtAnomalous 2025 debt and extreme leverage materially elevate perceived financial risk and suggest data volatility or one-off events. Such balance-sheet instability undermines credibility with lenders and partners and could complicate financing or strategic transactions needed to advance the clinical program.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.98 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $32.39M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is May 14, 2026 which is in 72 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Feb 18, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.68.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 8,457,967 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.368%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cel-Sci Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $250.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-68.94%
12-Months-Change
Fundamentals
Return on Equity
-176.32%
Trailing 12-Months
Asset Growth
-15.51%
Trailing 12-Months
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
2.52% Insiders
3.74% Mutual Funds
0.09% Other Institutional Investors
90.89% Public Companies and
Individual Investors